

August 13, 2026

The Honorable Robert F. Kennedy, Jr.
Secretary
U.S. Department of Health and Human Services
200 Independence Avenue, SW
Washington, D.C., 20201

Dear Secretary Kennedy:

I write to you with ongoing concerns over your failure to disclose the Trump administration's secret pricing deals with drug companies — even as new information comes to light indicating that President Trump's highly touted deals are doing little to reduce drug costs and providing huge benefits to Big Pharma.

During your testimony before the Senate Finance Committee in April, you gave me your commitment that you would “make the[se] deals available, except for proprietary information and trade secrets.”¹ I sent you a letter soon after that exchange officially requesting copies of the deals the administration negotiated with drug manufacturers.² It took you three months to respond — and you have not provided any clarity on this matter.³ Your response neither provides copies of the questionable agreements, nor answers questions about your unproven claims that the website is saving patients money.⁴ Indeed, it raises fresh questions about whether the Trump administration's savings estimates are reliable.

In July of 2025, President Trump sent letters to 17 big pharmaceutical companies urging them to comply with his “Most-Favored-Nations” (MFN) prescription drug pricing initiative.⁵ In

¹ U.S. Senate Committee on Finance, “The President's Fiscal Year 2027 Department of Health and Human Services Budget,” April 22, 2026, 1:26:36-1:26:42, <https://www.finance.senate.gov/hearings/the-presidents-fiscal-year-2027-department-of-health-and-human-services-budget>.

² Letter from U.S. Senator Elizabeth Warren to HHS Secretary Robert F. Kennedy, Jr., April 28, 2026, https://www.warren.senate.gov/wp-content/uploads/media/doc/warren_letter_to_hhs_secretary_following_up_on_senate_finance_hearing_commitments.pdf.

³ Letter from HHS Secretary Robert F. Kennedy, Jr. to U.S. Senator Elizabeth Warren, July 28, 2026, [on file with the Office of Senator Elizabeth Warren].

⁴ *Id.*

⁵ The White House, “President Trump Demands America First Prescription Drug Pricing,” August 4, 2025, <https://www.whitehouse.gov/releases/2025/08/president-trump-demands-america-first-prescription-drug-pricing>.

September of 2025, he announced the administration had made its first deal with Pfizer,⁶ and additional agreements with the remaining sixteen drug companies were announced over the following seven months.⁷

In February, you stood beside the President as he launched “TrumpRx,” a website that claims to offer Americans discounted prescription drugs at prices negotiated by the President through his MFN initiative.⁸ However, as we discussed during the Senate Finance Committee hearing in April, many of the brand drugs offered on TrumpRx had generic alternatives available elsewhere at significantly lower costs.⁹ While TrumpRx has since added a wider selection of generic drugs and added some information about generic alternatives to select pages,¹⁰ not every brand drug on TrumpRx with an existing generic alternative has that alternative readily available on the site, and a recent analysis finds that the TrumpRx deals represent only around 12 percent of brand drugs made by participating Big Pharma companies.¹¹ Thus, consumers still risk overpaying for branded drugs despite the availability of cheaper generics.

Additionally, the same week you released your response to me, the White House made an unfounded claim that TrumpRx had already saved more than \$700 million for American patients.¹² This savings estimate reveals that the website has saved the average prescription drug user only about \$5 — a pittance compared to the extraordinarily high costs charged by drug manufactures. On its face, this is an admission of failure. But your response to me raises questions about whether even that estimate was made up out of thin air. In my April letter, I asked that you provide metrics to back up your boasts about millions of Americans using the website.¹³ But in

⁶ The White House, “Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients,” September 30, 2025, <https://www.whitehouse.gov/fact-sheets/2025/09/fact-sheet-president-donald-j-trump-announces-first-deal-to-bring-most-favored-nation-pricing-to-american-patients>.

⁷ The White House, “Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients,” December 19, 2025, <https://www.whitehouse.gov/fact-sheets/2025/12/fact-sheet-president-donald-j-trump-announces-largest-developments-to-date-in-bringing-most-favored-nation-pricing-to-american-patients>; The White House, “Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients,” April 23, 2026, <https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-announces-deal-with-regeneron-to-bring-most-favored-nation-pricing-to-american-patients>.

⁸ NPR, “Trump struck deals with 16 drug companies. But they're still raising prices this year,” Sydney Lupkin, January 16, 2026, <https://www.npr.org/2026/01/16/nx-s1-5678915/trumprx-pharma-drug-price-deals-list-prices>; Stat News, “TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics,” John Wilkerson, J. Emory Parker, Chelsea Cirruzzo, et al., February 6, 2026, <https://www.statnews.com/2026/02/06/trumprx-discount-drug-website-undercut-by-cheaper-generics>.

⁹ U.S. Senate Committee on Finance, “The President’s Fiscal Year 2027 Department of Health and Human Services Budget,” April 22, 2026, 1:22:13-1:27:16, <https://www.finance.senate.gov/hearings/the-presidents-fiscal-year-2027-department-of-health-and-human-services-budget>.

¹⁰ TrumpRx, “Frequently Asked Questions,” accessed August 3, 2026, <https://trumprx.gov>.

¹¹ NPR, “TrumpRx promised a supermarket for cheaper drugs but delivered a boutique,” Sydney Lupkin, July 16, 2026, <https://www.npr.org/2026/07/16/nx-s1-5894947/trump-rx-medicine-drugs-health-care-pfizer-low-prices-gilead>.

¹² Fox Business, “Americans save more than \$700M on prescription medications through TrumpRx, White House says,” Edward Lawrence, July 24, 2026, <https://www.foxbusiness.com/politics/americans-save-more-than-700m-prescription-medications-through-trumprx-white-house-says>; Georgetown University Health Policy Institute, “Prescription Drugs,” last accessed August 12, 2026, <https://hpi.georgetown.edu/rxdrugs>.

¹³ Letter from U.S. Senator Elizabeth Warren to HHS Secretary Robert F. Kennedy, Jr., April 28, 2026, https://www.warren.senate.gov/imo/media/doc/warren_letter_to_hhs_secretary_following_up_on_senate_finance_hearing_commitments.pdf.

your July response, you told me that TrumpRx “does not store any patient, health, or prescription information.”¹⁴ Absent this information, it is simply impossible to verify the accuracy of any claims of savings. The administration’s claim is also questionable in light of a recent filing by TrumpRx partner GoodRx, which reveals that GoodRx views the impact of TrumpRx on its business to be minimal, saying that utilization of TrumpRx “has not had a material impact on GoodRx’s] business to date.”¹⁵

Meanwhile, drug manufacturers that entered into these deals have benefited from huge tariff exemptions for branded drugs¹⁶ and received vouchers to fast-track approvals for new products.¹⁷ That is on top of billion-dollar handouts President Trump and Republicans in Congress gave to the pharmaceutical industry last year in their tax law.¹⁸

And instead of deploying valuable taxpayer resources to lower drug prices for Americans, news reports indicate that the Trump administration is “launching a full-scale charm offensive across Europe to persuade governments...to pay more for medicines” — and using the threat of tariffs to strong-arm countries if that does not work.¹⁹ This is a huge win for giant drug companies that will reap billions in additional revenues from higher prices abroad,²⁰ while doing absolutely nothing to lower drug prices for Americans in need. Americans are paying more on everything from school supplies to furniture thanks to Trump’s across-the-board tariffs,²¹ and instead of negotiating deals to help workers and American families, he’s using that leverage to go to bat for Big Pharma.

¹⁴ Letter from HHS Secretary Robert F. Kennedy, Jr. to U.S. Senator Elizabeth Warren, July 28, 2026, [on file with the Office of Senator Elizabeth Warren].

¹⁵ United States Securities and Exchange Commission, Form 10-Q for GoodRx Holdings, Inc., August 5, 2026, <https://investors.goodrx.com/static-files/917181d9-f051-409d-be4b-736f9ce1ad19>.

¹⁶ Reuters, “Drugmakers face 100% tariff unless they cut prices or produce drugs in US,” Ahmed Aboulenein, April 2, 2026, <https://www.reuters.com/sustainability/boards-policy-regulation/drugmakers-face-100-tariff-unless-they-cut-prices-or-produce-drugs-us-2026-04-02>.

¹⁷ Stat News, “The Trump administration is turning drug review into make-a-deal,” Daniel Carpenter, Thomas Hwang, and Aaron S. Kesselheim, November 21, 2026, <https://www.statnews.com/2025/11/21/fda-national-priority-voucher-program-deals-ethics>.

¹⁸ Letter from Congressional Budget Office Director Phillip L. Swagel to Senator Ron Wyden and Representatives Frank Pallone and Richard Neal, October 20, 2025, <https://www.cbo.gov/system/files/2025-10/61818-Pallone-et-al-orphan-drugs-letter-10-20-25.pdf>.

¹⁹ Office of the United States Trade Representative, “Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany’s Persistent Underpayment for Innovative Pharmaceutical Products,” June 18, 2026, <https://ustr.gov/sites/default/files/files/Press/Releases/2026/Germany%20Pharma%20Section%20301%20Initiation%20FRN%206-18-26.pdf>; Politico, “Trump’s drug pricing war comes for Germany,” Caroline Hug and Hans Von Der Burchard, June 9, 2026, <https://www.politico.eu/article/us-donald-trumps-drug-pricing-war-comes-for-germany>.

²⁰ UK Parliament, “What is the UK-US pharmaceuticals deal?,” June 18, 2026, <https://commonslibrary.parliament.uk/research-briefings/cbp-10850>; BBC, “US and UK agree zero tariffs deal on pharmaceuticals,” December 1, 2025, Simon Jack, Nick Triggle, and Rachel Clun, <https://www.bbc.com/news/articles/cn0k520v4xro>.

²¹ CBS News, “Families face higher costs as back-to-school season nears,” Megan Cerullo, July 19, 2026, <https://www.cbsnews.com/news/back-to-school-supply-lunch-costs-tariffs>; NPR, “What’s happening with furniture prices? A tale of \$399 couches and tariffs,” Alina Selyukh, November 7, 2025, <https://www.npr.org/2025/11/07/nx-s1-5566671/furniture-price-trump-tariffs>.

It is no surprise then that drug manufacturers, including the ones participating in these MFN deals, continue to raise drug prices undeterred. In January, prices increased for 872 drugs,²² and for hundreds more throughout the spring and summer.²³ Moreover, drug companies are reportedly “already leveraging the pressure from the U.S. to try to get European countries to pay more” for prescription drugs.²⁴ In a statement following the administration’s initiation of its Section 301 investigation against Germany, the Pharmaceutical Research and Manufacturers of America, the trade association for pharmaceutical manufacturers, demanded other countries “take action to pay their fair share” and “encourag[ed] the Administration to continue pursuing strong trade agreements” to stop other countries from “free riding.”²⁵ This strategy raises serious questions about the administration’s priorities when it comes to lowering drug prices.

These concerns became even more pressing following an alarming admission by Centers for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz that President Trump’s MFN deals with pharmaceutical manufacturers will “expire after [the Trump administration] is done.”²⁶ This was new — and explosive — information that makes the Trump deals look even worse. You committed to bringing “radical transparency” to the Department of Health and Human Services (HHS),²⁷ but your ongoing refusal to release these deals raises questions about whether the Trump administration is trying to hide the fact that it is giving billion-dollar handouts to Big Pharma without getting anything meaningful in return for Americans.

Americans deserve to know whether the deals the administration is cutting with Big Pharma will lower their prescription drug costs — or just further enrich big drug companies. Despite my request that you make the administration’s MFN deals with giant drug companies public, and your commitment to do so, you have yet to follow through. The American public deserves to know if — in exchange for the Trump administration’s valuable giveaways to drug manufacturers — they are saving anything more than pennies on the dollar. I once again ask that you meet your commitment and provide these agreements and the following information no later than August 27, 2026:

1. Please provide copies of all negotiated deals made with drug manufacturers that list their brand drugs on TrumpRx. For any information that is redacted because you claim it is confidential or a trade secret, please provide a clear explanation for doing so.

²² NPR, “Trump struck deals with 16 drug companies. But they’re still raising prices this year,” Sydney Lupkin, January 16, 2026, <https://www.npr.org/2026/01/16/nx-s1-5678915/trumprx-pharma-drug-price-deals-list-prices>.

²³ 46brooklyn, “This is the Way ... to Analyze Changes in Brand Drug List Prices,” last accessed August 11, 2026, <https://www.46brooklyn.com/branddrug-boxscore>.

²⁴ Stat News, “Trump’s drive to get Europe to pay more for drugs creates uncertainty for countries, patients,” Andrew Joseph, March 2, 2026, <https://www.statnews.com/2026/03/02/trump-drug-prices-mfn-deal-europe-confidential-price-problem>.

²⁵ PhRMA, “PhRMA Statement on USTR’s Initiation of Section 301 Investigation Against Germany, press release, June 18, 2026, <https://www.phrma.org/resources/phrma-statement-on-ustr-s-initiation-of-section-301-investigation-against-germany>.

²⁶ Forbes Breaking News, “Oz Asked About Codifying MFN Status: ‘Could You Describe The Debate Within The Administration?’,” June 2, 2026, 0:35, https://www.youtube.com/watch?v=zRPvMH_ghR0.

²⁷ The American Presidency Project, “Remarks During a Swearing-in Ceremony for Robert F. Kennedy, Jr., as Secretary of Health and Human Services and an Exchange With Reporters,” February 13, 2025, <https://www.presidency.ucsb.edu/documents/remarks-during-swearing-ceremony-for-robert-f-kennedy-jr-secretary-health-and-human>.

2. Was Dr. Oz's statement that the negotiated deals expire at the end of President Trump's term accurate?
 - a. What is HHS doing to ensure that pharmaceutical companies do not immediately raise prices back to their pre-negotiated level after their contractual obligations from these deals expire?
 - b. What is HHS doing to ensure that any purported benefits to consumers from these deals will not disappear after the deals expire?
 - c. Are there any provisions in these deals preventing drug manufacturers from rapidly increasing prices once the deals expire?
3. Is the reporting that the administration is working to strike secret deals with European countries, including Germany, to increase drug prices accurate?²⁸
 - a. Which countries are the administration pressuring to raise their drug prices?
 - b. Is the administration attempting to strike these deals with European governments at the request of major pharmaceutical companies?
 - c. Have any of the drug companies with which the administration has struck these drug pricing deals influenced or participated in the administration's negotiations with European countries?
4. In June, the United States Trade Representative opened a Section 301 investigation into Germany's drug pricing policies and practices, which could potentially result in pharmaceutical tariffs.²⁹ Is the administration planning on opening additional Section 301 investigations into other countries' drug pricing policies and practices in an effort to push other governments to increase their drug spending?
5. Did the pharmaceutical companies with whom President Trump struck deals request that TrumpRx omit information about the availability of cheaper generic options?
6. How many Americans have visited the TrumpRx website since February 5, 2026?
7. What is the average amount of savings per visitor to the website? Please provide a detailed description of how this estimate was developed.

Sincerely,



Elizabeth Warren
United States Senator

²⁸ Politico, "Trump's drug pricing war comes for Germany," Caroline Hug and Hans von der Burchard, June 9, 2026, <https://www.politico.eu/article/us-donald-trumps-drug-pricing-war-comes-for-germany>.

²⁹ Office of the United States Trade Representative, "Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products," June 18, 2026, <https://ustr.gov/sites/default/files/files/Press/Releases/2026/Germany%20Pharma%20Section%20301%20Initiation%20FRN%206-18-26.pdf>; Fierce Pharma, "US to investigate Germany's proposed drug spending reforms," Fraiser Kansteiner, June 22, 2026, <https://www.fiercepharma.com/pharma/us-investigate-germanys-proposed-drug-spending-reforms>.